

Original Article

Cite this article: Roldan L *et al* (2024).

Cannabis use and cognitive biases in people with first-episode psychosis and their siblings. *Psychological Medicine* **54**, 4095–4105. <https://doi.org/10.1017/S0033291724001715>

Received: 25 October 2023

Revised: 3 May 2024

Accepted: 14 June 2024

First published online: 22 November 2024

Keywords:

aberrance salience; cannabis; cognition; facial recognition; jumping to conclusions

Corresponding author:

L. Roldan;

Email: laroldan@ucm.es;

C. Arango;

Email: carango@hggm.es;

C. M. Díaz-Caneja;

Email: covadonga.martinez@iisgm.com

Cannabis use and cognitive biases in people with first-episode psychosis and their siblings

L. Roldan¹, T. Sánchez-Gutiérrez², I. Fernández-Arias¹, E. Rodríguez-Toscano³, G. López⁴, J. Merchán-Naranjo⁴, A. Calvo¹, M. Rapado-Castro^{4,5}, M. Parellada⁴, C. Moreno⁴, L. Ferraro⁶, D. La Barbera⁶, C. La Cascia⁶, G. Tripoli⁶, M. Di Forti^{7,8}, R.M. Murray⁹, D. Quattrone⁷, C. Morgan^{10,8}, C. Gayer-Anderson¹⁰, P. B. Jones¹¹, H.E. Jongsma¹¹, J.B. Kirkbride¹², J. van Os^{13,9,14}, P. García-Portilla¹⁵, S. Al-Halabi¹⁶, J. Bobes¹⁵, L. de Haan¹⁷, M. Bernardo¹⁸, J.L. Santos¹⁹, J. Sanjuán²⁰, M. Arrojo²¹, A. Szoke^{22,23}, B.P. Rutten¹³, S. A. Stilo^{9,24}, I. Tarricone²⁵, A. Lasalvia²⁶, S. Tosato²⁷, P.-M. Llorca²⁷, P. Rossi Menezes²⁸, J-P Selten¹³, A. Tortelli²⁹, E. Velthorst³⁰, C.M. Del-Ben³¹, C. Arango⁴ and C. M. Díaz-Caneja⁴

Abstract

Background. Cannabis use and familial vulnerability to psychosis have been associated with social cognition deficits. This study examined the potential relationship between cannabis use and cognitive biases underlying social cognition and functioning in patients with first episode psychosis (FEP), their siblings, and controls.

Methods. We analyzed a sample of 543 participants with FEP, 203 siblings, and 1168 controls from the EU-GEI study using a correlational design. We used logistic regression analyses to examine the influence of clinical group, lifetime cannabis use frequency, and potency of cannabis use on cognitive biases, accounting for demographic and cognitive variables.

Results. FEP patients showed increased odds of facial recognition processing (FRP) deficits (OR = 1.642, CI 1.123–2.402) relative to controls but not of speech illusions (SI) or jumping to conclusions (JTC) bias, with no statistically significant differences relative to siblings. Daily and occasional lifetime cannabis use were associated with decreased odds of SI (OR = 0.605, CI 0.368–0.997 and OR = 0.646, CI 0.457–0.913 respectively) and JTC bias (OR = 0.625, CI 0.422–0.925 and OR = 0.602, CI 0.460–0.787 respectively) compared with lifetime abstinence, but not with FRP deficits, in the whole sample. Within the cannabis user group, low-potency cannabis use was associated with increased odds of SI (OR = 1.829, CI 1.297–2.578, FRP deficits (OR = 1.393, CI 1.031–1.882, and JTC (OR = 1.661, CI 1.271–2.171) relative to high-potency cannabis use, with comparable effects in the three clinical groups.

Conclusions. Our findings suggest increased odds of cognitive biases in FEP patients who have never used cannabis and in low-potency users. Future studies should elucidate this association and its potential implications.

Background

Cannabis use can increase the risk of psychosis (Di Forti *et al.*, 2015; Di Forti *et al.*, 2019; Karpov, Lindgren, Kieseppa, Wegelius, & Suvisaari, 2021; Luzi, Morrison, Powell, di Forti, & Murray, 2008; Murray, Paparelli, Morrison, Marconi, & Di Forti, 2013) and its prevalence is higher in patients diagnosed with schizophrenia (Bersani, Orlandi, Kotzalidis, & Pancheri, 2002; Hartz *et al.*, 2014), bipolar disorder, depressive and anxiety disorders, and post-traumatic stress disorder (PTSD) (Koenfal, Gabrys, & Porath, 2019; Lev-Ran, Le Foll, McKenzie, George, & Rehm, 2013) than in healthy controls.

Some cognitive and reasoning biases have been reported across the psychosis continuum including people with first episode psychosis (FEP), chronic psychosis, clinical and familial high risk for psychosis, and non-clinical samples with psychotic-like experiences (Henquet *et al.*, 2022; Langdon, Still, Connors, Ward, & Catts, 2014; Linney, Peters, & Ayton, 1998; Moritz, Van Quaquebeke, & Lincoln, 2012; Van Dael *et al.*, 2006). These cognitive biases could increase psychosis risk by affecting the perception of others, decision-making about social situations, the meaning attributed to certain social stimuli, and real-life functioning (Green, Horan, & Lee, 2019; Mucci *et al.*, 2021).

Aberrant salience is the unusual or incorrect assignment of meaning to neutral stimuli, which can favor the development of attentional biases that may in turn lead to the perception that the environment is dangerous and to the development of paranoid ideation (Howes &

© The Author(s), 2024. Published by Cambridge University Press. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.



Murray, 2014; Kapur, 2003). Experimental illusion studies have focused on the paradigm of hearing voices in neutral random signals (white noise) in the absence of actual speech (speech illusion, SI) (Galdos et al., 2011).

Other cognitive biases have also consistently been reported in patients with schizophrenia (Hofer, Biedermann, Yalcin, & Fleischhacker, 2010; Lee et al., 2013), such as the jumping to conclusion (JTC) reasoning bias: under conditions of uncertainty, people with delusions use less information to arrive at a decision and express greater confidence in their judgment than controls (Dudley, Taylor, Wickham, & Hutton, 2016; Garety & Freeman, 2013; Lincoln, Ziegler, Mehl, & Rief, 2010; Murray et al., 2020; So, Siu, Wong, Chan, & Garety, 2016; Tripoli et al., 2021).

Also, deficits in facial recognition processing (discrimination, encoding, and recognition) have been found in people with schizophrenia (Archer, Hay, & Young, 1992; Shin et al., 2008; van 't Wout, Aleman, Kessels, Laroi, & Kahn, 2004; Walther et al., 2009), with milder degrees of facial recognition impairments observed in non-affected first-degree relatives of patients with schizophrenia (Li, Chan, Zhao, Hong, & Gong, 2010), thus suggesting that this could be a potential endophenotypic marker of psychosis (Fusar-Poli et al., 2022a; Soria Bauser et al., 2012; Tripoli et al., 2022).

Despite consistent evidence supporting the presence of impairments across cognition and social cognition in schizophrenia (Green et al., 2019; Velthorst et al., 2017), the effect of cannabis use on cognitive and social cognitive functioning in patients with FEP and their siblings is still controversial (Arnold, Allott, Farhall, Killackey, & Cotton, 2015; Bruins, Pijnenborg, investigators, Visser, & Castelein, 2021; Clausen et al., 2014; Meijer et al., 2012). Most studies report better or similar neuropsychological functioning in people with schizophrenia and FEP that use cannabis than in those who do not (Rabin, Zakzanis, & George, 2011; Wobrock et al., 2013; Yucel et al., 2012). A recent study in the EU-GEI sample using the degraded facial affect recognition task reported better facial emotion recognition processing in cannabis users with schizophrenia, their siblings, and healthy controls, both for total scores and for specific emotion recognition (neutral, happy, fearful, and angry) relative to non-users (Fusar-Poli et al., 2022b). However, other studies have observed poorer cognitive performance (D'Souza et al., 2005; Mata et al., 2008) or no differences in some cognitive tasks in people with schizophrenia using cannabis (Ahuir et al., 2021; Jockers-Scherubl et al., 2007; Sevy et al., 2007).

As social skills may be necessary for patients to acquire and use some substances, especially in context where access is more restricted, some researchers suggest that cannabis use in people with FEP could correlate with better social abilities, more drug taking opportunities, and better neurocognitive functioning (Arnold et al., 2015; Menendez-Miranda et al., 2019; Rodriguez-Sanchez et al., 2010; Yucel et al., 2012). Indeed, previous research in the EU-GEI sample suggests that better premorbid social and cognitive functioning could contribute to the likelihood of beginning to use cannabis before psychosis onset in patients with FEP (Ferraro et al., 2020).

In this study, we sought to examine for the first time the relationship between cannabis use and speech illusions, facial recognition processing deficits, and jumping to conclusions in patients with FEP, their non-psychotic siblings, and controls. These biases may underlie processes in social cognitive deficits in schizophrenia related with positive symptoms of schizophrenia such as

persecutory delusions and auditory hallucinations. Following previous studies, we hypothesized that lifetime cannabis use would correlate with lower odds of cognitive biases relative to lifetime abstinence. As secondary objectives, we aimed to explore the association of frequency of cannabis use and cannabis potency with the odds of cognitive biases in cannabis users.

Methods

Study design

Members of a large, international, multisite, observational study, *The European Network of National Schizophrenia Networks Studying Gene-Environment Interactions* (EU-GEI), recruited participants between May 2010 and April 2015 from 17 catchment areas in 6 countries (Brazil, France, Italy, the Netherlands, Spain, and the United Kingdom). Study goals include analyzing the effects of genetic, environmental, and clinical variables and their interaction on the development, severity, and outcome of schizophrenia and other psychotic disorders. The EU-GEI team recruited a subset of people with FEP for a concurrent case-control study and controls from the same catchment areas. Additionally, they recruited patients' siblings to focus on the role of gene-environment interaction of the vulnerability and severity of psychosis in a family-based setting. Detailed study procedures are available in (Gayer-Anderson et al., 2020; Jongsma et al., 2018).

Participants

The EU-GEI study sample included 1130 participants with FEP who attended mental health services in the catchment areas. Inclusion criteria for patients were: (1) diagnosis of non-organic psychotic disorder, (2) 18–64 years of age, (3) resident within one of the study catchment areas at the time of their first presentation. Exclusion criteria included: (1) presence of psychotic symptoms due to acute intoxication (ICD10: F1X.5) or organic psychosis (ICD10: F09), (2) previous contact with mental health services because of psychotic symptoms outside of the study period.

We also recruited siblings of FEP participants, aged 18 years or older ($N = 265$) via communications with the patient and/or his or her reference clinician. We excluded siblings if they presented current or past psychotic disorders (including a psychosis diagnosis within the time frame of the study) or if they had received treatment with antipsychotic medication.

We recruited volunteers from the same catchment areas and same age range as patients for the control sample by using a mixture of random and quota sampling to maximize the representativeness of samples in each catchment area. A total of 1497 controls agreed to participate in the study. We excluded controls if they had received psychotic disorder diagnoses, including during the study, or had undergone treatment with antipsychotic medication. More information about the recruitment procedures is available elsewhere (Di Forti et al., 2019; Gayer-Anderson et al., 2020; van Os et al., 2014).

For the purposes of this study, we included participants that had complete data on cannabis use and complete assessments of each of the three cognitive biases. This yielded a final sample size of 543 participants with FEP, 203 siblings, and 1168 controls (see online Supplementary Figure 1).

Local ethical committees of all sites approved the study at all the study sites. All participants gave written informed consent before entering the study. The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.

Measures

Demographic and clinical measures

We used the modified version of the Medical Research Council (MRC) socio-demographic scale to collect socio-demographic data (Mallett, Leff, Bhugra, Pang, & Zhao, 2002). Diagnoses were operationalized through the 90-item computerized Operational CRITeria (OPCRIT) system for psychosis (McGuffin, Farmer, & Harvey, 1991; Williams, Farmer, Ackenheil, Kaufmann, & McGuffin, 1996) in the group of patients. To estimate full scale-IQ scores (including Digit Symbol Substitution, Arithmetic, BlockDesign, and Information subtests) we used an abbreviated and adapted version of the WAIS (Velthorst et al., 2013). We measured clinical symptoms with the CAPE scale (Konings, Bak, Hanssen, van Os, & Krabbendam, 2006; Mossaheb et al., 2012), a questionnaire designed to rate self-reports of positive, negative, and depressive psychotic experiences. Duration of untreated psychosis (in weeks) was estimated with the Notting-ham Onset Schedule (Singh et al., 2005).

Measures of cannabis use

Information about cannabis use was collected with the Cannabis Experience Questionnaire (CEQ) further modified for the EUGEI study (CEQ_{EU-GEI}) (Di Forti et al., 2019). The CEQ was modified to (1) include questions to assess dependence for cannabis use and other drugs, and (2) to describe use and changes in cannabis use over specific age periods. We asked participants whether they had ever used cannabis in their lifetime and, if so, we asked about the frequency, type (high or low potency), and duration of use based on the current pattern of use, or, when there was no current use of cannabis, based on the pattern of use that described best the overall pattern of cannabis use. We subdivided cannabis use frequency into three levels: daily use, occasional use (ranging from only once or twice in a lifetime to more than once a week), and never use (absence of lifetime cannabis use) (Di Forti et al., 2019; Ferraro et al., 2020).

We used data on the concentration of Δ^9 -tetrahydrocannabinol (THC) in the different types of cannabis available across Europe from in the European Monitoring Centre for Drugs and Drug Addiction 2016 report to create a measure of cannabis potency. A cutoff of THC = 10% was used to define the potency variable [high ($\geq 10\%$) v. low ($<10\%$) potency] based on the mean THC concentration expected in the different types of cannabis available across the sites (for further information, please see online Supplementary Methods and Di Forti et al. (2019)).

Cognitive bias assessment

To explore speech illusions and aberrance salience we used the White Noise Task. The task consists of a random presentation of 75 audio fragments, 25 of which include just white noise, 25 that contain white noise and barely audible speech, and 25 that include white noise mixed with clearly audible speech, with positive, negative, or neutral affective content. Participants listened to the sounds binaurally through headphones. The length of the task

was approximately 15 min. After each fragment, we asked participants to press specific buttons on a keyboard which reflected what they heard: (1) speech with positive content; (2) speech with negative content; (3) speech with neutral content; (4) absence of speech, and (5) presence of speech but uncertain to choose between positive, negative, or neutral emotional valence. Speech illusion was defined as a white noise fragment in which any speech was heard (option 1, 2, 3, or 5 in just white noise fragments). Only 25 out of 75 fragments contained white noises, so the maximum score for speech illusion was 25. A dichotomous variable was then calculated based on a cut-off of two or more speech illusions independently of the emotional valence attributed by the participant (Catalan et al., 2014).

We used the Benton Facial Recognition Test (BFRT) (Benton, 1994; Benton and Van Allen, 1968) to assess facial recognition processing. The BFRT is a face discrimination test in which participants are required to match a target face to either one face keeping the same viewpoint and lighting conditions (6 items) or three or six faces presented simultaneously that vary in viewpoints and lighting (16 items). The total score is calculated based on the total correct answers given (maximum score is 54). Deficits in facial recognition processing were defined as scores of 20 or fewer correct answers in the BFRT (Duchaine & Nakayama, 2006).

The Drawing to Decisions (DTD) index (Garety et al., 2015; So et al., 2016) was used to assess Jumping To Conclusion (JTC) bias. We obtained this index from the probabilistic reasoning (beads) task, with 60:40 task ratios. Two jars of beads were shown to participants in equal but opposite ratios (85 red and 15 blue and vice versa). Both jars were hidden, and researchers told participants that individual beads were drawn consecutively from one jar. The beads were actually presented in a prespecified sequence. Participants were required to either decide from which jar the beads had come or postpone the decision (up to a maximum of 20 beads). The key outcome variable employed as an index of the JTC bias was the number of 'Draws-To-Decision' (DTD); the lower the DTD, the greater the JTC bias. For the purposes of this study JTC bias was defined as a DTD index of 2 or less in the beads task (Klein & Pinkham, 2018), as participants are considered to have an extreme JTC bias when a decision is made after presentation of two or fewer items (Garety et al., 2005).

Statistical analysis

We calculated means and standard deviations for continuous variables and frequency and percentages for categorical variables. For the comparisons in cognitive biases and frequency of cannabis use between FEP patients, siblings, and controls, we used Chi-square tests. We used ANOVA analyses to compare quantitative socio-demographic variables between the three groups. We used the Bonferroni test for post-hoc pairwise comparisons.

Considering the uneven distribution of the cognitive biases, we decided on a dichotomous analysis and used cutoffs based on previous studies using customary definitions of cognitive biases from the literature. To examine the influence of group and frequency of cannabis use on cognitive biases variables we conducted three sets of stratified logistic regression model analyses, as we were interested in analyzing the effect of cannabis use on the three cognitive biases separately. We adjusted our analyses for demographic variables: sex, age, years in education, ethnicity, employment (yes/no), migrant status (yes/no), and intelligence quotient (IQ). Variables were included in two models; Model 1 included clinical

group (FEP, sibling, or control), demographic variables (sex, age, years of education, employment, and migration), and IQ; Model 2 added the frequency of lifetime cannabis use (never/occasional/daily) and the interaction between the frequency and the clinical group. We performed secondary analyses to examine the effects of frequency of use (occasional v. daily) and potency of cannabis (high v. low) in the group of cannabis users only.

We conducted supplementary analyses in the FEP group to additionally adjust Model 2 for the (i) severity of negative psychotic symptomatology (CAPE Negative) and (ii) Duration of Untreated Psychosis (DUP).

The level of statistical significance was set at $p < 0.05$. All statistical analyses were conducted using SPSS 25.

Results

Demographic and clinical characteristics

Socio-demographic characteristics of the sample are described in Table 1. We observed significant differences between the three clinical groups in sex, age, country, ethnicity, years in education, estimated IQ, and frequency of cannabis use. The FEP sample not analyzed in this study ($n = 587$; see online Supplementary Figure 1) showed significantly lower IQ, included lower rates of white and mixed ethnic groups and higher rates of black and north African ethnic groups and migrants, and higher rates of high-potency cannabis use relative to the FEP sample analyzed in the study ($n = 543$). Relative to the sibling and control samples not analyzed in the study, the sibling sample not analyzed in the study was significantly older and had fewer years in education and the control sample not analyzed in the study was older and included higher rates of white ethnic group. We did not find any significant differences in any other demographic or cannabis use variables on cognitive bias variables between the samples analyzed and not analyzed in this study.

Cannabis use

Participants with FEP were less likely to have never used cannabis (v. occasional and daily use) than siblings and controls. Thus, 38.9% of FEPs, 59.6% of siblings, and 52.3% of controls had never used cannabis ($\chi^2_{(4)} = 176.6 < 0.001$). Patients were also more likely to have used cannabis daily (29.3%) relative to controls (6.9%) and siblings (5.9%); ($\chi^2_{(2)} = 176.6$; $p < 0.001$). Occasional use of cannabis was more frequent in the control (40.8%) than in the FEP group (31.9%); ($\chi^2_{(4)} = 176.6 < 0.001$) (see Table 1). In the subgroup of cannabis users, high potency (64%) was more frequent than low potency use (36%) in siblings ($\chi^2_{(2)} = 8.248$; $p < 0.016$), with no significant differences in the FEP or control groups.

Association of clinical group and frequency of cannabis use with cognitive biases

FEP patients presented a higher proportion of all cognitive biases than siblings and controls. Across the whole sample, cognitive biases in the three tests were significantly more frequent in participants that had never used cannabis relative to those with occasional or daily use. Occasional users showed cognitive biases less frequently than daily users (all $p < 0.001$) (Table 2 and online Supplementary Figure 1).

Table 3 shows the logistic regression models of *speech illusions* (SI). In model 1, clinical group did not show a significant association with the presence of SI. In model 2, we found that frequency of cannabis use was a predictive factor in the model, with no significant effects of clinical group or the interaction between clinical group and frequency of use. Specifically, occasional use of cannabis correlated with 0.64-fold decreased odds (OR = 0.646; 95% CI 0.457–0.9113), and daily use of cannabis with 0.60-fold decreased odds (OR = 0.605; 95% CI 0.368–0.997) of having SI relative to never use of cannabis. The resulting final model explained 16.5% of the variance of the presence of SI ($R^2 = 0.165$, $p < 0.001$). Secondary analyses conducted in cannabis users showed a significant effect of low-potency cannabis on SI (OR = 1.829; 95%CI 1.297–2.578). Frequency of cannabis use (occasional v. daily) was no longer a predictive factor in the model and the effects decreased substantially. We found no significant interaction between clinical group and the frequency of cannabis use or potency (see online Supplementary Table 1).

Table 4 shows the logistic regression models for the *BFR*. In model 1, the FEP group showed significantly higher odds of facial recognition processing (FRP) deficits compared with controls (OR = 1.467; 95%CI 1.122–1.918), with no significant differences with their siblings. After controlling for frequency of cannabis in model 2, the difference in patients and controls remained significant, with comparable effects (OR = 1.642; 95%CI 1.123–2.402), while frequency of cannabis use was not a significant predictor in the model. The interaction effect between clinical group and frequency of cannabis use in the model was also not significant. The final model accounted for 12.1% of the explained variance ($R^2 = 0.121$, $p < 0.001$). Secondary analyses including cannabis users only showed a comparable effect of clinical group (OR = 1.588; 95%CI 1.104–2.284, a significant effect of potency (OR = 1.393; 95%CI 1.031–1.882), and no significant effects of frequency of cannabis use or the interaction between clinical group and frequency of use or potency in the models (see online Supplementary Table 2).

Table 5 shows the logistic regression analyses for the *DTD*. We did not find a significant effect of clinical group on JTC bias in Model 1 or 2. After including frequency of use in Model 2, participants who used cannabis occasionally or daily showed significantly lower odds of JTC bias compared with abstainers in the whole sample (OR = 0.602; 95% CI 0.460–0.787) and (OR = 0.625; 95% CI 0.422–0.925), respectively. There was no significant interaction between clinical group and frequency of cannabis use in the model. This model explained 19.3% of the variance ($R^2 = 0.193$, $p < 0.001$).

Secondary analyses in the subgroup of cannabis users showed low-potency as a significant predictor of DTD (OR = 1.661; 95% CI 1.271–2.171), with no significant effect of frequency of use (occasional v. daily) or the interaction between clinical group and frequency of use or potency in the model (see online Supplementary Table 3).

Supplementary analyses in the FEP sample adjusted for the duration of untreated psychosis or the score on the negative CAPE subscale found comparable effects for the frequency of cannabis use variables and similar predictive capacity to those from the main models (see online Supplementary Tables 4–6).

Conclusions

To the best of our knowledge, this is the first study to examine the odds of speech illusions, facial recognition deficits, and jumping to conclusions biases in a large international sample of patients

Table 1. Demographic and clinical characteristics of the sample: patients with first-episode psychosis, siblings, and controls

Variables	FEP <i>N</i> = 543	Siblings <i>N</i> = 203	Controls <i>N</i> = 1168	Test (<i>df</i>)	<i>p</i>
Gender					
Male, <i>N</i> (%)	333 (61.3)	68 (47.6)	547 (46.8)	χ^2 (2) = 54.5	<0.001
Female, <i>N</i> (%)	210 (38.7)	135 (66.5)	621 (53.2)		
Age, mean (s.d.)	31.5 (11)	30.7 (9.4)	35.7 (12.9)	<i>F</i> (2, 1911) = 31.6	<0.001
Country					
UK, <i>N</i> (%)	27 (5)	4 (2)	285 (24.4)	χ^2 (10) = 196.4	<0.001
The Netherlands, <i>N</i> (%)	111 (20.4)	53 (26.1)	175 (15)		
Spain, <i>N</i> (%)	119 (21.9)	54 (26.6)	168 (14.4)		
France, <i>N</i> (%)	38 (7)	5 (2.5)	112 (9.6)		
Italy, <i>N</i> (%)	74 (13.6)	6 (3)	142 (12.2)		
Brazil, <i>N</i> (%)	174 (32)	81 (39.9)	286 (24.5)		
Ethnicity					
White, <i>N</i> (%)	372 (68.5)	153 (75.4)	905 (77.5)	χ^2 (10) = 28.5	<0.001
Black, <i>N</i> (%)	50 (9.2)	13 (6.4)	96 (8.2)		
Mixed, <i>N</i> (%)	78 (14.4)	31 (15.3)	104 (8.9)		
Asian, <i>N</i> (%)	15 (2.8)	1 (0.5)	27 (2.3)		
North African, <i>N</i> (%)	16 (2.9)	4 (2)	19 (1.6)		
Other, <i>N</i> (%)	12 (2.2)	1 (0.5)	17 (1.5)		
Years education, mean (s.d.)	12.7 (4.4)	13.7 (4.6)	14.8 (4.2)	<i>F</i> (2, 1898) = 44.5	<0.001
Occupational status					
Ever employed: Yes, <i>N</i> (%)	493 (90.8)	190 (93.6)	1093 (93.6)	χ^2 (2) = 4.524	0.104
Ever employed: No, <i>N</i> (%)	50 (9.2)	13 (6.4)	75 (6.4)		
Frequency of cannabis use					
Never, <i>N</i> (%)	211(38.9)	121 (59.6)	611 (52.3)	χ^2 (4) = 176.6	<0.001
Occasional use, <i>N</i> (%)	173 (31.9)	70 (34.5)	476 (40.8)		
Daily use, <i>N</i> (%)	159 (29.3)	12 (5.9)	81 (6.9)		
Migrant					
Yes, <i>N</i> (%)	110 (20.3)	29 (14.3)	232 (19.9)	χ^2 (2) = 3.814	0.149
No, <i>N</i> (%)	433 (79.7)	174 (85.7)	936 (80.1)		
IQ, mean (s.d.)	87.6 (17.7)	96.3 (14.7)	103.6 (17.6)	<i>F</i> (2) = 148.4	<0.001
CAPE negative, mean (s.d.)	27.1 (7.9)	21.3 (6.1)	21.2 (5.1)	<i>F</i> (2) = 180.17	<0.001
DUP in weeks, mean (s.d.) ^a	27.2 (55.1)	—	—	—	—

CAPE, Community Assessment of Psychic Experiences scale; DUP, Duration of Untreated Psychosis; FEP, First-Episode Psychosis; IQ, Intelligence Quotient.

^aOutlier cases for DUP were not included in the analysis (*n* = 14).

with FEP, their siblings, and healthy controls. We found that FEP patients showed greater likelihood of facial recognition processing (FRP) deficits than siblings and controls. Contrary to previous findings in schizophrenia (Hoffman, 1999; Hoffman et al., 2007; Holt et al., 2006; Kapur, 2003), we did not find significantly higher odds of speech illusions (SI) and JTC in FEP patients relative to siblings and controls, in this large international study.

Together with theory of mind, facial processing is critical for meaningful social interactions and for guiding social behavior and deficits in FRP may underlie some of the social cognition deficits in patients with psychosis (Comparelli et al., 2014; Green et al., 2012; Mucci et al., 2021; Velthorst et al., 2017). In this study, we found more frequent FRP deficits in individuals with FEP than in their siblings and controls, thus suggesting that

FRP deficits could be a specific marker related to psychosis but not genetically shared with siblings. This is consistent with previous studies reporting increased likelihood of cognitive biases related to facial processing deficits in individuals with psychosis relative to their siblings or controls (Fusar-Poli et al., 2022b; Shin et al., 2008; Tripoli et al., 2022; van 't Wout et al., 2004) and with previous evidence in the EU-GEI sample. For example, Fusar-Poli et al. (2022a, 2022b) found that deficits in facial emotion recognition (measured by total Degraded Facial Affect Recognition task scores) were greater in individuals with schizophrenia than in siblings, who showed greater deficits than healthy controls. In our study, we did not find differences between siblings and controls regarding FRP deficits. Our divergent findings may be due to differing tasks or a more diagnostically

Table 2. Percentage of participants with cognitive biases (speech illusions, facial recognition processing deficit (BFR), and jumping to bias (DTD) according to clinical group and cannabis use

	Group			χ^2 ; <i>p</i>	Cannabis use			χ^2 ; <i>p</i>
	FEP	Siblings	Controls		Daily	Occasional	Never	
Speech illusion	27.6	24.6	18.8	17.83;<0.001	21	14.7	27.7	39.99;<0.001
BFR	36.1	24.6	21.8	17.67;<0.001	24.2	20.6	31	23.32;<0.001
DTD	56.5	50.7	45.6	17.83;<0.001	48.8	39.2	57	51.91;<0.001

BFR, Benton facial recognition; DTD, drawing to decision.

heterogenous sample of FEP and their siblings in our study (Fusar-Poli et al., 2022b).

We did not find an increased likelihood of aberrant salience in FEP patients than in siblings or healthy controls. Previous studies found that proneness to aberrant salience correlated with familial vulnerability for psychosis, and was more likely found in delusional schizophrenia patients than in non-delusional and healthy subjects or their siblings, thus suggesting a familial liability to psychosis associated with aberrant salience (Catalan et al., 2014; Galdos et al., 2011; Hoffman, 1999; Hoffman et al., 2007; Holt et al., 2006; Schepers et al., 2019). Also, previous studies focusing on FEP patients showed higher rates of speech illusions than the control group, contrary to our findings, and speech illusions correlated with positive symptomatology (Catalan et al., 2014). Our results may differ in part because most of the studies mentioned did not include FEP-only samples or studied smaller samples with more unspecific tasks to measure these cognitive processes.

Contrary to our JTC findings, previous literature reports that patients with psychosis frequently use less information to arrive at a decision than controls and show increased risk of JTC bias (Ahui et al., 2021; Dudley et al., 2016; Henquet et al., 2022; Hofer et al., 2010; Lee et al., 2013; Ross, McKay, Coltheart, & Langdon, 2015). Similarly, previous studies based on the EU-GEI WP6 sample including schizophrenia patients, their siblings and

healthy controls, showed increased odds of JTC bias in both patients and siblings relative to controls, thus suggesting an association between JTC bias and familial risk for psychosis (Henquet et al., 2022). Our different results may be because some of these studies were conducted in chronic schizophrenia samples or did not include FEP patients only. Indeed, a previous study observed a higher prevalence of JTC bias in individuals with schizophrenia than in individuals with recent-onset psychosis. Inconsistent findings could also result from previous studies not including IQ as a potential confounding variable in the analyses. In fact, the FEP group showed increased odds of JCT bias relative to controls in our sample in the analyses not adjusted by IQ, with no significant effect of the clinical group after controlling for this variable.

Our overall results confirmed our hypothesis that lifetime abstention from cannabis correlated with the presence of SI and JTC bias compared to daily or occasional cannabis use, with a comparable effect across FEP patients, siblings, and controls. As social skills could enable FEP patients to acquire and maintain a drug habit, or facilitate the use of drugs in social environments (Menendez-Miranda et al., 2019), cannabis use in people with FEP could be indicative of better or preserved social abilities, more drug taking opportunities, better neurocognitive functioning, and therefore, fewer and less significant cognitive biases (Arnold et al., 2015; Rodriguez-Sanchez et al., 2010; Yucel et al.,

Table 3. Logistic regression models for speech illusion

Speech illusion (yes)	β	Error	Sig.	OR [CI 95%]
Model 1 $\chi^2_{(13)} = 18\,122$, $p < 0.001$; $R^2 = 0.149$				
Group (controls)			0.650	
FEP	0.121	0.150	0.420	1.129 [0.841–1.516]
Siblings	0.133	0.200	0.507	1.142 [0.771–1.692]
Model 2 $\chi^2_{(17)} = 201\,605$; $p < 0.001$; $R^2 = 0.165$				
Group (controls)			0.097	
FEP	0.259	0.218	0.236	1.295 [0.844–1.987]
Siblings	−0.705	0.456	0.122	0.494 [0.202–1.208]
Cannabis use (never)			0.034	
Occasional	−0.437	0.176	0.013	0.646 [0.457–0.913]
Daily	−0.502	0.254	0.049	0.605 [0.368–0.997]

Note. All the models are adjusted for sex, age, ethnicity, years in education, employment, migration, and estimated intelligence quotient (IQ). Age was significant in Model 1 ($p < 0.001$); ethnicity and education were significant in Models 1 and 2 ($p < 0.001$) (not shown in the Table).

Model 1 = Group + sex, age, ethnicity, years in education, employment, migrant; Model 2 = Model 1 + frequency of cannabis use + interaction group $\times$ frequency of cannabis use ($p > 0.05$ for all interactions studied, data not shown in the Table). Significant results are highlighted in bold.

Presence of aberrance salience was considered as presence of speech illusion (speech illusion/yes) using a cutoff of two or more speech illusions.

R^2 = Nagelkerke's r^2 ; Hosmer–Lemeshow test $p > 0.05$ for Models 1 and 2.

CI, confidence interval; FEP, first-episode psychosis; OR, odds ratio.

Table 4. Logistic regression models for facial recognition processing (FRP) deficit

BFR (Low)	β	Error	Sig.	OR [CI 95%]
Model 1 $\chi^2_{(13)} = 139.737; p < 0.001; R^2 = 0.111$				
Group (controls)			0.018	
FEP	0.383	0.137	0.005	1.467 [1.122–1.918]
Siblings	0.066	0.192	0.732	1.068 [0.733–1.556]
Model 2 $\chi^2_{(17)} = 153.272; p < 0.001; R^2 = 0.121$				
Group (controls)			0.003	
FEP	0.496	0.194	0.011	1.642 [1.123–2.402]
Siblings	−0.656	0.397	0.099	0.519 [0.238–1.130]
Cannabis use (never)			0.157	
Occasional	−0.154	0.162	0.222	0.821 [0.598–1.127]
Daily	−0.442	0.237	0.056	0.637 [0.401–1.011]

Note. All the models are adjusted for sex, age, ethnicity, years in education, employment, migration, and estimated intelligence quotient (IQ). Age was significant in Model 1 ($p < 0.001$); ethnicity and education were significant in Models 1 and 2 ($p < 0.001$); IQ was significant in Model 1 ($p < 0.001$) and 2 ($p = 0.002$) (not shown in Table).

Model 1 = Group + sex, age, ethnicity, education, employment, migrant; Model 2 = Model 1 + Frequency of cannabis use + Interaction group $\times$ frequency of cannabis use ($p > 0.05$ in all interactions studied, data not shown in the Table). Significant results are highlighted in bold.

Deficits in FRP deficits were defined as scores of 20 or less in the BFR test (BFR low).

R^2 = Nagelkerke's r^2 ; Hosmer–Lemeshow test $p > 0.05$ for Models 1 and 2.

BFR, Benton facial recognition; CI, confidence interval; FEP, first-episode psychosis; OR, odds ratio.

2012). In this respect, a previous analysis of the EU-GEI sample observed better social adjustment prior to FEP in occasional and daily cannabis users relative to non-users. This difference was not observed in the control group (Ferraro et al., 2020). Previous literature on patients with psychosis has also reported premorbid differences between cannabis users and non-users, with cannabis users potentially developing psychosis at an earlier age through an alternative pathway with less cognitive vulnerability (both neurocognitive and social cognitive) (Myles, Myles, & Large, 2016; Schnakenberg Martin et al., 2016).

Taken together, we conclude that FEP cannabis users could constitute a group of less cognitively impaired individuals (Arnold et al., 2015) in whom cannabis use would be an important contributor to psychosis risk (Ferraro et al., 2020; Ferraro et al., 2019; Ferraro et al., 2013). In fact, we found no significant differences in cognitive biases between occasional and daily use in cannabis users, supporting the idea that FEP cannabis users and nonusers may represent distinct populations with differing premorbid load and risk factors, rather than there being a global direct protective effect of cannabis use on social cognition. Exploring

Table 5. Logistic regression models for jumping to conclusions bias (drawing to decision index)

DTD (≤ 2 draws)	β	Error	Sig.	OR [CI 95%]
Model 1 $\chi^2_{(13)} = 266.438; p < 0.001; R^2 = 0.184$				
Group (controls)			0.941	
FEP	0.032	0.128	0.802	1.033 [0.803–1.328]
Siblings	0.050	0.171	0.768	1.052 [0.753–1.469]
Model 2 $\chi^2_{(17)} = 280.908; p < 0.001; R^2 = 0.193$				
Group (controls)			0.340	
FEP	0.232	0.173	0.179	1.261 [1.261 [0.899–1.769]
Siblings	0.230	0.262	0.379	1.259 [0.754–2.103]
Cannabis Use (Never)			<0.001	
Occasional	−0.508	0.137	<0.001	0.602 [0.460–0.787]
Daily	−0.471	0.201	0.019	0.625 [0.422–0.925]

Note. All the models are adjusted for sex, age, ethnicity, years in education, employment, migration, and estimated intelligence quotient (IQ). Age was significant in Model 1 ($p < 0.001$); ethnicity, education, and IQ were significant in Models 1 and 2 ($p < 0.001$) (not shown in the Table).

Model 1 = group + sex, age, ethnicity, education, employment, migrant; Model 2 = Model 1 + frequency of cannabis use + Interaction group $\times$ frequency of cannabis use ($p > 0.05$ for all the interactions studied, data not shown).

Jumping to conclusions bias was defined as a DTD index of 2 or less draws in the beads task.

R^2 = Nagelkerke's r^2 ; Hosmer–Lemeshow test $p > 0.05$ for Models 1 and 2.

CI, confidence interval; DTD, drawing to decision; FEP, first-episode psychosis; OR, odds ratio.

if these associations exist both before and after the FEP warrants future longitudinal studies.

Among lifetime cannabis users, the use of low-potency cannabis was significantly associated with increased odds of SI, FRP, and JTC relative to high-potency cannabis use, with comparable effects across FEP patients, their siblings, and controls. Potent cannabis varieties, with high concentrations of delta-9-tetrahydrocannabinol (Δ^9 -THC), correlate with the most harm to mental health (Di Forti et al., 2015; Freeman et al., 2018) and recent studies based on the EU-GEI sample have shown how FEP patients with a history of daily use of high-potency cannabis present with more positive symptoms, compared with those who never used cannabis or used low potency variants (Quattrone et al., 2021). However, the relationship between the potency of cannabis and neurocognition is still unclear, and growing evidence suggests that two of the main cannabinoids, THC and CBD, display opposing neural, cognitive, and behavioral effects (Iseger & Bossong, 2015). Moreover, a study of cannabis users implicated THC in impaired facial emotional recognition, while CBD improved facial emotional recognition and attenuated THC-induced impairment (Hindocha et al., 2015). Our results show that FEP patients who use high potency variants of cannabis show less cognitive bias than those who use low potency cannabis, contrary to previous findings. One possible explanation could be related with the gateway hypothesis; FEP patients who smoke low potency variants of cannabis and show social cognitive impairment may not progress to later consumption of higher potency variants of cannabis.

This study has several limitations. First, cross-sectional studies limit analyses to a descriptive level and we could not assess causality. We also lacked a direct measure of social skills. Future studies using methodologies that allow for a more in-depth analysis and using a prospective design could clarify the longitudinal association between cannabis use and the risk of cognitive biases, as well as ascertain the specific role of social skills in this association. Second, cannabis use was not corroborated with the collection of biological samples. Instead, we used self-reporting tools, with a risk of recall bias and we did not conduct specific memory assessments. Notwithstanding, previous studies reported that the use of interviews to collect information about drug use in the adult population is generally reliable and valid (Curran et al., 2019; Freeman et al., 2014; Van Dorn, Desmarais, Scott Young, Sellers, & Swartz, 2012). Third, although we analyzed a large sample of participants with FEP, their siblings, and healthy controls, our findings may not be generalizable to all FEP and sibling populations. Exclusion of participants from the analysis due to lacking information on cannabis use or cognitive bias variables could influence the representativeness of our findings. Fourth, in keeping with other EU-GEI publications we classified cannabis use frequency in three categories (never use, occasional use, daily use). However, the heterogeneity in the “occasional use” category may have influenced our results. Finally, despite potential effect of antipsychotic treatments and other interventions on cognitive functioning in first-episode psychosis (Allot et al., 2023), we did not consider pharmacological treatments and other cognitive or psychosocial interventions in our analyses. Future studies should assess the effect of these factors on the association between cannabis use and cognitive biases.

In conclusion, FRP deficits were more prevalent in FEP patients than in their siblings or control participants, with no significant differences between the three groups in other cognitive biases such as speech illusions or JTC bias in the adjusted

analyses. Cognitive biases were more frequent in cannabis abstainers and in participants who used low potency of cannabis relative to daily and occasional users and high potency participants respectively. Our findings suggest that FEP patients who have never used cannabis on a regular basis would be more likely to present cognitive biases. Considering the detrimental effects of cannabis on psychosis risk even beyond genetic predisposition (Ferraro et al., 2023), future studies should elucidate this association and its potential clinical implications further.

Supplementary material. The supplementary material for this article can be found at <https://doi.org/10.1017/S0033291724001715>.

Acknowledgements. We thank the patients and their families for their participation in this study.

Funding statement. The European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI) Project was supported by grant agreement HEALTH-F2-2010-241909 (Project EU-GEI) from the European Community's Seventh Framework Programme. This work was partially supported by the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (ISCIII) (PI19/01024, PI20/00721, PI22/01824, PI23/00625), CIBER -Consorcio Centro de Investigación Biomédica en Red- (CB/07/09/0023), co-financed by the European Union and ERDF Funds from the European Commission, ‘A way of making Europe’, financed by the European Union - NextGenerationEU (PMP21/00051), Madrid Regional Government (S2022/BMD-7216 AGES 3-CM), European Union Structural Funds, EU Seventh Framework Program, H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No.101034377, Project PRISM-2), and Horizon Europe (HORIZON-HLTH-2021-STAYHLTH-01-02, grant agreement No 101057182, project Youth-GEMs), the National Institute of Mental Health of the National Institutes of Health under Award Number 1U01MH124639-01 (Project ProNET) and Award Number 5P50MH115846-03 (project FEP-CAUSAL), Fundación Familia Alonso, and Fundación Alicia Koplowitz. MRC is a Ramon y Cajal Research Fellow (RYC-2017-23144), Spanish Ministry of Science, Innovation and Universities and was supported by a NARSAD independent investigator grant (no. 24628) from the Brain and Behavior Research Foundation. MRC has received grant support from Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (PI18/00753, PI21/00701) and the Alicia Koplowitz Foundation. CDC holds a Juan Rodés Grant from Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (JR19/00024). JBK is supported by the National Institute of Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre (BRC).

Competing interests. Celso Arango has been a consultant to or has received honoraria or grants from Acadia, Angelini, Gedeon Richter, Janssen Cilag, Lundbeck, Minerva, Otsuka, Roche, Sage, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion and Takeda. Miquel Bernardo has been a consultant for, received grant/research support and honoraria from, and been on the speakers/advisory board of ABBiotics, Adamed, Angelini, Casen Recordati, Janssen-Cilag, Menarini, Rovi and Takeda. Covadonga M. Díaz-Caneja has received honoraria from Angelini and support to attend conferences from Janssen and Angelini. Peter B. Jones declares grant support from NIHR (0616-20003) and consulted for MSD. Carmen Moreno has received honoraria as a consultant and/or advisor and/or for lectures from Angelini, Esteve, Exeltis Janssen, Lundbeck, Neuraxpharm, Nuvelution, Otsuka, Pfizer, Servier and Sunovion outside the submitted work.

¹Department of Personality, Assessment and Clinical Psychology, School of Psychology, Universidad Complutense de Madrid, Spain; ²Department of Psychology, University of Córdoba, Spain; ³Department of Experimental Psychology, Cognitive processes and Speech therapy, School of Psychology, Universidad Complutense de Madrid (UCM); Madrid, Spain; ⁴Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health,

Hospital General Universitario Gregorio Marañón, IISGM, CIBERSAM, School of Medicine, Universidad Complutense, Madrid, Spain; ⁵Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, 161 Barry Street, Carlton South, Victoria 3053, Australia; ⁶Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), Psychiatry Section, University of Palermo, Palermo, Italy; ⁷Social, Genetic, and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, England; ⁸ESRC Centre for Society and Mental Health, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK; ⁹Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK; ¹⁰Department of Health Services and Population Research, Institute of Psychiatry, Psychology and Neuroscience, King's College London, England; ¹¹Department of Psychiatry, University of Cambridge; ¹²CAMEO Early Intervention Service, Cambridgeshire & Peterborough NHS Foundation Trust, Cambridge, CB21 5EF, UK; ¹³PsyLife Group, Division of Psychiatry, University College London, 6th Floor, Maple House, 149 Tottenham Court Road, London W1T 7NF, UK; ¹⁴Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Center, Maastricht, Netherlands; ¹⁵Department Psychiatry, Brain Centre Rudolf Magnus, Utrecht University Medical Centre, Utrecht, The Netherlands; ¹⁶Department of Medicine -Psychiatry, Universidad de Oviedo, ISPA, INEUROPA, CIBERSAM, Oviedo, Spain; ¹⁷Department of Psychology, University of Oviedo, Spain; ¹⁸Amsterdam UMC, University of Amsterdam, Academic Psychiatric Centre, Early Psychosis Department, Arkin, Amsterdam, The Netherlands; ¹⁹Barcelona Clinic Schizophrenia Unit, Hospital Clinic, Departament de Medicina, Institut de Neurociències (UBNeuro), Universitat de Barcelona (UB), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBERSAM, ISCIII, Barcelona, Spain; ²⁰Department of Psychiatry, Servicio de Psiquiatría Hospital "Virgen de la Luz," Cuenca, Spain; ²¹Department of Psychiatry, Hospital Clínico Universitario de Valencia, INCLIVA, CIBERSAM, School of Medicine, Universidad de Valencia, Valencia, Spain; ²²Department of Psychiatry, Psychiatric Genetic Group, Instituto de Investigación Sanitaria de Santiago de Compostela, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain; ²³Univ Paris Est Creteil, INSERM, IMRB, Fondation FondaMental, F-94010 Creteil, France; ²⁴AP-HP, Hôpitaux Universitaires "H. Mondor", DMU IMPACT, F-94010 Creteil, France; ²⁵Department of Mental Health and Addiction Services, ASP Crotone, Crotone, Italy; ²⁶Bologna Transcultural Psychosomatic Team (BoTPT), Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna; ²⁷Section of Psychiatry, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy; ²⁸Université Clermont Auvergne, EA 7280, Clermont-Ferrand 63000, France; ²⁹Department of Preventive Medicine, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil; ³⁰Etablissement Public de Santé Maison Blanche, Paris 75020, France; ³¹Mental Health Service Organization 'GGZ Noord-Holland-Noord', Department of Research, the Netherlands and ³²Division of Psychiatry, Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil

References

- Ahuir, M., Crosas, J. M., Estrada, F., Zabala, W., Perez-Munoz, S., Gonzalez-Fernandez, A., ... Labad, J. (2021). Cognitive biases are associated with clinical and functional variables in psychosis: A comparison across schizophrenia, early psychosis and healthy individuals. *Revista de Psiquiatria y Salud Mental (English Edition)*, 14(1), 4–15. doi:10.1016/j.rpsm.2020.07.005
- Allott, K., Yuen, H. P., Baldwin, L., O'Donoghue, B., Fornito, A., Chopra, S., ... Wood, S. J. (2023). Effects of risperidone/paliperidone versus placebo on cognitive functioning over the first 6 months of treatment for psychotic disorder: Secondary analysis of a triple-blind randomised clinical trial. *Translational Psychiatry*, 13(1), 199.
- Archer, J., Hay, D. C., & Young, A. W. (1992). Face processing in psychiatric conditions. *British Journal of Clinical Psychology*, 31(1), 45–61. doi:10.1111/j.2044-8260.1992.tb00967.x
- Arnold, C., Allott, K., Farhall, J., Killackey, E., & Cotton, S. (2015). Neurocognitive and social cognitive predictors of cannabis use in first-episode psychosis. *Schizophrenia Research*, 168(1–2), 231–237. doi:10.1016/j.schres.2015.07.051
- Benton, A. L. (1994). *Contributions to neuropsychological assessment: A clinical manual*. New York: Oxford University Press.
- Benton, A. L., & Van Allen, M. W. (1968). Impairment in facial recognition in patients with cerebral disease. *Transactions of the American Neurological Association*, 93, 38–42. doi.org/10.1016/S0010-9452(68)80018-8
- Bersani, G., Orlandi, V., Kotzalidis, G. D., & Pancheri, P. (2002). Cannabis and schizophrenia: Impact on onset, course, psychopathology and outcomes. *European Archives of Psychiatry and Clinical Neuroscience*, 252(2), 86–92. doi:10.1007/s00406-002-0366-5
- Catalan, A., Simons, C. J., Bustamante, S., Drukker, M., Madrazo, A., de Artaza, M. G., ... Gonzalez-Torres, M. A. (2014). Novel evidence that attributing affectively salient signal to random noise is associated with psychosis. *PLoS One*, 9(7), e102520. doi:10.1371/journal.pone.0102520
- Clausen, L., Hjorthøj, C. R., Thorup, A., Jeppesen, P., Petersen, L., Bertelsen, M., & Nordentoft, M. (2014). Change in cannabis use, clinical symptoms and social functioning among patients with first-episode psychosis: A 5-year follow-up study of patients in the OPUS trial. *Psychological Medicine*, 44(1), 117–126. doi:10.1017/S0033291713000433
- Comparelli, A., De Carolis, A., Corigliano, V., Di Pietro, S., Trovini, G., Granese, C., ... Girardi, P. (2014). Symptom correlates of facial emotion recognition impairment in schizophrenia. *Psychopathology*, 47(1), 65–70. doi:10.1159/000350453
- Curran, H. V., Hindocha, C., Morgan, C. J. A., Shaban, N., Das, R. K., & Freeman, T. P. (2019). Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects? *Psychological Medicine*, 49(9), 1574–1580. doi:10.1017/S003329171800226X
- Di Forti, M., Marconi, A., Carra, E., Fraietta, S., Trotta, A., Bonomo, M., ... Murray, R. M. (2015). Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: A case-control study. *The Lancet. Psychiatry*, 2(3), 233–238. doi:10.1016/S2215-0366(14)00117-5
- D'Souza, D. C., Abi-Saab, W. M., Madonick, S., Forselius-Bielen, K., Doersch, A., Braley, G., ... Krystal, J. H. (2005). Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction. *Biological Psychiatry*, 57(6), 594–608. doi:10.1016/j.biopsych.2004.12.006
- Duchaine, B. C., & Nakayama, K. (2006). Developmental prosopagnosia: A window to content-specific face processing. *Current Opinion in Neurobiology*, 16(2), 166–173. doi:10.1016/j.conb.2006.03.003
- Dudley, R., Taylor, P., Wickham, S., & Hutton, P. (2016). Psychosis, delusions and the "jumping to conclusions" reasoning bias: A systematic review and meta-analysis. *Schizophrenia Bulletin*, 42(3), 652–665. doi:10.1093/schbul/sbv150
- Di Forti, M., Quattrone, D., Freeman, T. P., Tripoli, G., Gayer-Anderson, C., & Quigley, H., ... EU-GEI WP2 Group. (2019). The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): A multicentre case-control study. *The Lancet. Psychiatry*, 6(5), 427–436. doi:10.1016/S2215-0366(19)30048-3
- Jongsma, H. E., Gayer-Anderson, C., Lasalvia, A., Quattrone, D., Mule, A., & Szoke, A., ... European Network of National Schizophrenia Networks Studying Gene-Environment Interactions Work Package, G. (2018). Treated incidence of psychotic disorders in the multinational EU-GEI study. *JAMA Psychiatry*, 75(1), 36–46. doi:10.1001/jamapsychiatry.2017.3554
- Ferraro, L., Russo, M., O'Connor, J., Wiffen, B. D., Falcone, M. A., Sideli, L., ... Di Forti, M. (2013). Cannabis users have higher premorbid IQ than other patients with first onset psychosis. *Schizophrenia Research*, 150(1), 129–135. doi:10.1016/j.schres.2013.07.046
- Ferraro, L., Murray, R. M., Di Forti, M., Quattrone, D., Tripoli, G., Sideli, L., ... La Cascia, C. (2019). IQ differences between patients with first episode psychosis in London and Palermo reflect differences in patterns of cannabis use. *Schizophrenia Research*, 210, 81–88. doi:10.1016/j.schres.2019.06.004
- Ferraro, L., La Cascia, C., Quattrone, D., Sideli, L., Matranga, D., Capuccio, V., ... Di Forti, M. (2020). Premorbid adjustment and IQ in patients with first-episode psychosis: A multisite case-control study of their relationship with cannabis use. *Schizophrenia Bulletin*, 46(3), 517–529. doi:10.1093/schbul/sbz077
- Ferraro, L., Quattrone, D., La Barbera, D., La Cascia, C., Morgan, C., Kirkbride, J. B., ... Murray, R. M. (2023). First-Episode psychosis patients who

- deteriorated in the premorbid period do not have higher polygenic risk scores than others: A cluster analysis of EU-GEI data. *Schizophrenia Bulletin*, 49(1), 218–227. doi:10.1093/schbul/sbac100
- Freeman, T. P., Morgan, C. J., Hindocha, C., Schafer, G., Das, R. K., & Curran, H. V. (2014). Just say 'know': How do cannabinoid concentrations influence users' estimates of cannabis potency and the amount they roll in joints? *Addiction*, 109(10), 1686–1694. doi:10.1111/add.12634
- Freeman, T. P., van der Pol, P., Kuijpers, W., Wisselink, J., Das, R. K., Rigter, S., ... Lynskey, M. T. (2018). Changes in cannabis potency and first-time admissions to drug treatment: A 16-year study in the Netherlands. *Psychological Medicine*, 48(14), 2346–2352. doi:10.1017/S0033291717003877
- Fusar-Poli, L., Pries, L. K., van Os, J., Erzini, G., Delespaul, P., Kenis, G., ... Guloksuz, S. (2022a). Examining facial emotion recognition as an intermediate phenotype for psychosis: Findings from the EUGEI study. *Progress in Neuropsychopharmacology and Biological Psychiatry*, 113, 110440. doi:10.1016/j.pnpb.2021.110440
- Fusar-Poli, L., Pries, L. K., van Os, J., Radhakrishnan, R., Pence, A. Y., Erzini, G., ... Guloksuz, S. (2022b). The association between cannabis use and facial emotion recognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study. *Eur Neuropsychopharmacology*, 63, 47–59. doi:10.1016/j.euroneuro.2022.08.003
- Galdos, M., Simons, C., Fernandez-Rivas, A., Wichers, M., Peralta, C., Lataster, T., ... van Os, J. (2011). Affectively salient meaning in random noise: A task sensitive to psychosis liability. *Schizophrenia Bulletin*, 37(6), 1179–1186. doi:10.1093/schbul/sbq029
- Garety, P. A., & Freeman, D. (2013). The past and future of delusions research: From the inexplicable to the treatable. *British Journal of Psychiatry*, 203(5), 327–333. doi:10.1192/bjp.bp.113.126953
- Garety, P. A., Freeman, D., Jolley, S., Dunn, G., Bebbington, P. E., Fowler, D. G., ... Dudley, R. (2005). Reasoning, emotions, and delusional conviction in psychosis. *Journal of Abnormal Psychology*, 114(3), 373–384. doi:10.1037/0021-843X.114.3.373
- Garety, P., Waller, H., Emsley, R., Jolley, S., Kuipers, E., Bebbington, P., ... Freeman, D. (2015). Cognitive mechanisms of change in delusions: An experimental investigation targeting reasoning to effect change in paranoia. *Schizophrenia Bulletin*, 41(2), 400–410. doi:10.1093/schbul/sbu103
- Gayer-Anderson, C., Jongsma, H. E., Di Forti, M., Quattrone, D., Velthorst, E., de Haan, L., ... Morgan, C. (2020). The European network of national schizophrenia networks studying gene-environment interactions (EU-GEI): Incidence and first-episode case-control programme. *Social Psychiatry and Psychiatric Epidemiology*, 55(5), 645–657. doi:10.1007/s00127-020-01831-x
- Hartz, S. M., Pato, C. N., Medeiros, H., Cavazos-Reh, P., Sobell, J. L., & Knowles, J. A., ... Genomic Psychiatry Cohort, C. (2014). Comorbidity of severe psychotic disorders with measures of substance use. *JAMA Psychiatry*, 71(3), 248–254. doi:10.1001/jamapsychiatry.2013.3726
- Green, M. F., Bearden, C. E., Cannon, T. D., Fiske, A. P., Hellmann, G. S., Horan, W. P., ... Nuechterlein, K. H. (2012). Social cognition in schizophrenia, Part 1: Performance across phase of illness. *Schizophrenia Bulletin*, 38(4), 854–864. doi:10.1093/schbul/sbq171
- Green, M. F., Horan, W. P., & Lee, J. (2019). Nonsocial and social cognition in schizophrenia: Current evidence and future directions. *World Psychiatry*, 18(2), 146–161. doi:10.1002/wps.20624
- Wobrock, T., Falkai, P., Schneider-Axmann, T., Hasan, A., Galderisi, S., & Davidson, M., ... group, E. S. (2013). Comorbid substance abuse in first-episode schizophrenia: Effects on cognition and psychopathology in the EUFEST study. *Schizophrenia Research*, 147(1), 132–139. doi:10.1016/j.schres.2013.03.001
- Henquet, C., van Os, J., Pries, L. K., Rauschenberg, C., Delespaul, P., Kenis, G., ... Guloksuz, S. (2022). A replication study of JTC bias, genetic liability for psychosis and delusional ideation. *Psychological Medicine*, 52(9), 1777–1783. doi:10.1017/S0033291720003578
- Hindocha, C., Freeman, T. P., Schafer, G., Gardener, C., Das, R. K., Morgan, C. J., & Curran, H. V. (2015). Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: A randomised, double-blind, placebo-controlled study in cannabis users. *European Neuropsychopharmacology*, 25(3), 325–334. doi:10.1016/j.euroneuro.2014.11.014
- Hofer, A., Biedermann, F., Yalcin, N., & Fleischhacker, W. (2010). Neurocognition and social cognition in patients with schizophrenia or mood disorders. *Neuropsychiatrie: Klinik, Diagnostik, Therapie und Rehabilitation*, 24(3), 161–169.
- Hoffman, R. E. (1999). New methods for studying hallucinated 'voices' in schizophrenia. *Acta Psychiatrica Scandinavica Supplement*, 395, 89–94. doi:10.1111/j.1600-0447.1999.tb05987.x
- Hoffman, R. E., Woods, S. W., Hawkins, K. A., Pittman, B., Tohen, M., Preda, A., ... McGlashan, T. H. (2007). Extracting spurious messages from noise and risk of schizophrenia-spectrum disorders in a prodromal population. *British Journal of Psychiatry*, 191, 355–356. doi:10.1192/bjp.bp.106.031195
- Holt, D. J., Titone, D., Long, L. S., Goff, D. C., Cather, C., Rauch, S. L., ... Kuperberg, G. R. (2006). The misattribution of salience in delusional patients with schizophrenia. *Schizophrenia Research*, 83(2–3), 247–256. doi:10.1016/j.schres.2005.12.858
- Howes, O. D., & Murray, R. M. (2014). Schizophrenia: An integrated sociodevelopmental-cognitive model. *Lancet (London, England)*, 383(9929), 1677–1687. doi:10.1016/S0140-6736(13)62036-X
- Iseger, T. A., & Bossong, M. G. (2015). A systematic review of the antipsychotic properties of cannabidiol in humans. *Schizophrenia Research*, 162(1–3), 153–161. doi:10.1016/j.schres.2015.01.033
- Mucci, A., Galderisi, S., Gibertoni, D., Rossi, A., Rocca, P., & Bertolino, A., ... Italian Network for Research on, P. (2021). Factors associated with real-life functioning in persons with schizophrenia in a 4-year follow-up study of the Italian network for research on psychoses. *JAMA Psychiatry*, 78(5), 550–559. doi:10.1001/jamapsychiatry.2020.4614
- Jockers-Scherubl, M. C., Wolf, T., Radzei, N., Schlattmann, P., Rentzsch, J., Gomez-Carrillo de Castro, A., & Kuhl, K. P. (2007). Cannabis induces different cognitive changes in schizophrenic patients and in healthy controls. *Progress in Neuropsychopharmacology and Biological Psychiatry*, 31(5), 1054–1063. doi:10.1016/j.pnpb.2007.03.006
- Kapur, S. (2003). Psychosis as a state of aberrant salience: A framework linking biology, phenomenology, and pharmacology in schizophrenia. *American Journal of Psychiatry*, 160, 13–23.
- Karpov, B., Lindgren, M., Kieseppa, T., Wegelius, A., & Suvisaari, J. (2021). Cognitive functioning and cannabis use in first-episode psychosis. *Nordic Journal of Psychiatry*, 76(7), 551–558. doi:10.1080/08039488.2021.2018038
- Klein, H. S., & Pinkham, A. E. (2018). Examining reasoning biases in schizophrenia using a modified "Jumping to Conclusions" probabilistic reasoning task. *Psychiatry Research*, 270, 180–186. doi:10.1016/j.psychres.2018.09.020
- Koenig, S., Gabrys, R., & Porath, A. (2019). *Clearing the smoke on cannabis: Regular use and mental health*. Ottawa: Canadian Centre on Substance Use and Addiction. https://www.ccsa.ca/sites/default/files/2019-08/CCSACannabis-Use-Mental-HealthReport-2019-en_0.pdf
- Konings, M., Bak, M., Hanssen, M., van Os, J., & Krabbendam, L. (2006). Validity and reliability of the CAPE: A self-report instrument for the measurement of psychotic experiences in the general population. *Acta Psychiatrica Scandinavica*, 114(1), 55–61. doi:10.1111/j.1600-0447.2005.00741.x
- Langdon, R., Still, M., Connors, M. H., Ward, P. B., & Catts, S. V. (2014). Jumping to delusions in early psychosis. *Cognitive Neuropsychiatry*, 19(3), 241–256. doi:10.1080/13546805.2013.854198
- Lee, J., Altshuler, L., Glahn, D. C., Miklowitz, D. J., Ochsner, K., & Green, M. F. (2013). Social and nonsocial cognition in bipolar disorder and schizophrenia: Relative levels of impairment. *American Journal of Psychiatry*, 170(3), 334–341. doi:10.1176/appi.ajp.2012.12040490
- Lev-Ran, S., Le Foll, B., McKenzie, K., George, T. P., & Rehm, J. (2013). Cannabis use and cannabis use disorders among individuals with mental illness. *Comprehensive Psychiatry*, 54(6), 589–598. doi:10.1016/j.comppsy.2012.12.021
- Li, H., Chan, R. C., Zhao, Q., Hong, X., & Gong, Q. Y. (2010). Facial emotion perception in Chinese patients with schizophrenia and non-psychotic first-degree relatives. *Progress in Neuropsychopharmacology and Biological Psychiatry*, 34(2), 393–400. doi:10.1016/j.pnpb.2010.01.007
- Lincoln, T. M., Ziegler, M., Mehl, S., & Rief, W. (2010). The jumping to conclusions bias in delusions: Specificity and changeability. *Journal of Abnormal Psychology*, 119(1), 40–49. doi:10.1037/a0018118
- Linney, Y. M., Peters, E. R., & Ayton, P. (1998). Reasoning biases in delusion-prone individuals. *British Journal of Clinical Psychology*, 37(3), 285–302. doi:10.1111/j.2044-8260.1998.tb01386.x

- Luzi, S., Morrison, P. D., Powell, J., di Forti, M., & Murray, R. M. (2008). What is the mechanism whereby cannabis use increases risk of psychosis? *Neurotoxicity Research*, 14(2-3), 105–112. doi:10.1007/BF03033802
- Mallett, R., Leff, J., Bhugra, D., Pang, D., & Zhao, J. H. (2002). Social environment, ethnicity and schizophrenia. A case-control study. *Social Psychiatry and Psychiatric Epidemiology*, 37(7), 329–335. doi:10.1007/s00127-002-0557-4
- Mata, I., Rodriguez-Sanchez, J. M., Pelayo-Teran, J. M., Perez-Iglesias, R., Gonzalez-Blanch, C., Ramirez-Bonilla, M., ... Crespo-Facorro, B. (2008). Cannabis abuse is associated with decision-making impairment among first-episode patients with schizophrenia-spectrum psychosis. *Psychological Medicine*, 38(9), 1257–1266. doi:10.1017/S0033291707002218
- McGuffin, P., Farmer, A., & Harvey, I. (1991). A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. *Archives of General Psychiatry*, 48(8), 764–770. doi:10.1001/archpsyc.1991.01810320088015
- Menendez-Miranda, I., Garcia-Alvarez, L., Garcia-Portilla, M. P., Gonzalez-Blanco, L., Saiz, P. A., & Bobes, J. (2019). History of lifetime cannabis use is associated with better cognition and worse real-world functioning in schizophrenia spectrum disorders. *European Addiction Research*, 25(3), 111–118. doi:10.1159/000497317
- Moritz, S., Van Quaquebeke, N., & Lincoln, T. M. (2012). Jumping to conclusions is associated with paranoia but not general suspiciousness: A comparison of two versions of the probabilistic reasoning paradigm. *Schizophrenia Research Treatment*, 2012, 384039. doi:10.1155/2012/384039
- Mossaheb, N., Becker, J., Schaefer, M. R., Klier, C. M., Schloegelhofer, M., Papageorgiou, K., & Amminger, G. P. (2012). The Community Assessment of Psychic Experience (CAPE) questionnaire as a screening-instrument in the detection of individuals at ultra-high risk for psychosis. *Schizophrenia Research*, 141(2-3), 210–214. doi:10.1016/j.schres.2012.08.008
- Murray, R. M., Paparelli, A., Morrison, P. D., Marconi, A., & Di Forti, M. (2013). What can we learn about schizophrenia from studying the human model, drug-induced psychosis? *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, 162B(7), 661–670. doi:10.1002/ajmg.b.32177
- Murray, R. M., Mondelli, V., Stilo, S. A., Trotta, A., Sidel, L., Ajnakina, O., ... Di Forti, M. (2020). The influence of risk factors on the onset and outcome of psychosis: What we learned from the GAP study. *Schizophrenia Research*, 225, 63–68. doi:10.1016/j.schres.2020.01.011
- Myles, H., Myles, N., & Large, M. (2016). Cannabis use in first episode psychosis: Meta-analysis of prevalence, and the time course of initiation and continued use. *Australian & New Zealand Journal of Psychiatry*, 50(3), 208–219. doi:10.1177/0004867415599846
- Meijer, J. H., Dekker, N., Koeter, M. W., Quee, P. J., van Beveren, N. J., & Meijer, C. J., ... Outcome of Psychosis, I. (2012). Cannabis and cognitive performance in psychosis: A cross-sectional study in patients with non-affective psychotic illness and their unaffected siblings. *Psychological Medicine*, 42(4), 705–716. doi:10.1017/S0033291711001656
- Bruins, J., Pijnenborg, G. H. M., PHAMOUS investigators, Visser, E., & Castelein, S. (2021). The association of cannabis use with quality of life and psychosocial functioning in psychosis. *Schizophrenia Research*, 228, 229–234. doi:10.1016/j.schres.2020.11.059
- Quattrone, D., Ferraro, L., Tripoli, G., La Cascia, C., Quigley, H., Quattrone, A., ... Di Forti, M. (2021). Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: The EU-GEI case-control study. *Psychological Medicine*, 51(8), 1329–1337. doi:10.1017/S0033291720000082
- Rabin, R. A., Zakzanis, K. K., & George, T. P. (2011). The effects of cannabis use on neurocognition in schizophrenia: A meta-analysis. *Schizophrenia Research*, 128(1-3), 111–116. doi:10.1016/j.schres.2011.02.017
- Rodriguez-Sanchez, J. M., Ayasa-Arriola, R., Mata, I., Moreno-Calle, T., Perez-Iglesias, R., Gonzalez-Blanch, C., ... Crespo-Facorro, B. (2010). Cannabis use and cognitive functioning in first-episode schizophrenia patients. *Schizophrenia Research*, 124(1-3), 142–151. doi:10.1016/j.schres.2010.08.017
- Ross, R. M., McKay, R., Coltheart, M., & Langdon, R. (2015). Jumping to conclusions about the beads task? A meta-analysis of delusional ideation and data-gathering. *Schizophrenia Bulletin*, 41(5), 1183–1191. doi:10.1093/schbul/sbu187
- Schepers, E., Lousberg, R., Guloksuz, S., Pries, L. K., Delespaul, P., Kenis, G., ... van Os, J. (2019). White noise speech illusions: A trait-dependent risk marker for psychotic disorder? *Frontiers in Psychiatry*, 10, 676. doi:10.3389/fpsyt.2019.00676
- Schnakenberg Martin, A. M., Bonfils, K. A., Davis, B. J., Smith, E. A., Schuder, K., & Lysaker, P. H. (2016). Compared to high and low cannabis use, moderate use is associated with fewer cognitive deficits in psychosis. *Schizophrenia Research: Cognition*, 6, 15–21. doi:10.1016/j.scog.2016.09.001
- Sevy, S., Burdick, K. E., Visweswarajah, H., Abdelmessih, S., Lukin, M., Yechiam, E., & Bechara, A. (2007). Iowa gambling task in schizophrenia: A review and new data in patients with schizophrenia and co-occurring cannabis use disorders. *Schizophrenia Research*, 92(1-3), 74–84. doi:10.1016/j.schres.2007.01.005
- Shin, Y. W., Na, M. H., Ha, T. H., Kang, D. H., Yoo, S. Y., & Kwon, J. S. (2008). Dysfunction in configural face processing in patients with schizophrenia. *Schizophrenia Bulletin*, 34(3), 538–543. doi:10.1093/schbul/sbm118
- Singh, S. P., Cooper, J. E., Fisher, H. L., Tarrant, C. J., Lloyd, T., Banjo, J., ... Jones, P. (2005). Determining the chronology and components of psychosis onset: The Nottingham Onset Schedule (NOS). *Schizophrenia Research*, 80(1), 117–130. doi:10.1016/j.schres.2005.04.018
- So, S. H., Siu, N. Y., Wong, H. L., Chan, W., & Garety, P. A. (2016). 'Jumping to conclusions' data-gathering bias in psychosis and other psychiatric disorders – two meta-analyses of comparisons between patients and healthy individuals. *Clinical Psychology Review*, 46, 151–167. doi:10.1016/j.cpr.2016.05.001
- Soria Bauser, D., Thoma, P., Aizenberg, V., Brune, M., Juckel, G., & Daum, I. (2012). Face and body perception in schizophrenia: A configural processing deficit? *Psychiatry Research*, 195(1-2), 9–17. doi:10.1016/j.psychres.2011.07.017
- Tripoli, G., Quattrone, D., Ferraro, L., Gayer-Anderson, C., Rodriguez, V., La Cascia, C., ... Di Forti, M. (2021). Jumping to conclusions, general intelligence, and psychosis liability: Findings from the multi-centre EU-GEI case-control study. *Psychological Medicine*, 51(4), 623–633. doi:10.1017/S003329171900357X
- Tripoli, G., Quattrone, D., Ferraro, L., Gayer-Anderson, C., La Cascia, C., La Barbera, D., ... Murray, G. K. (2022). Facial emotion recognition in psychosis and associations with polygenic risk for schizophrenia: Findings from the multi-center EU-GEI case-control study. *Schizophrenia Bulletin*, 48(5), 1104–1114. doi:10.1093/schbul/sbac022
- Van Dael, F., Versmissen, D., Janssen, I., Myin-Germeyns, I., van Os, J., & Krabbendam, L. (2006). Data gathering: Biased in psychosis? *Schizophrenia Bulletin*, 32(2), 341–351. doi:10.1093/schbul/sbj021
- Van Dorn, R. A., Desmarais, S. L., Scott Young, M., Sellers, B. G., & Swartz, M. S. (2012). Assessing illicit drug use among adults with schizophrenia. *Psychiatry Research*, 200(2-3), 228–236. doi:10.1016/j.psychres.2012.05.028
- van Os, J., Rutten, B. P., Myin-Germeyns, I., Delespaul, P., Viechtbauer, W., van Zelst, C., ... Mirjanic, T. (2014). Identifying gene environment interactions in schizophrenia: Contemporary challenges for integrated, large-scale investigations. *Schizophrenia Bulletin*, 40(4), 729–736. doi:10.1093/schbul/sbu069
- van 't Wout, M., Aleman, A., Kessels, R. P., Laroi, F., & Kahn, R. S. (2004). Emotional processing in a non-clinical psychosis-prone sample. *Schizophrenia Research*, 68(2-3), 271–281. doi:10.1016/j.schres.2003.09.006
- Velthorst, E., Levine, S. Z., Henquet, C., de Haan, L., van Os, J., Myin-Germeyns, I., & Reichenberg, A. (2013). To cut a short test even shorter: Reliability and validity of a brief assessment of intellectual ability in schizophrenia – A control-case family study. *Cognitive Neuropsychiatry*, 18(6), 574–593. doi:10.1080/13546805.2012.731390
- Velthorst, E., Fett, A. J., Reichenberg, A., Perlman, G., van Os, J., Bromet, E. J., & Kotov, R. (2017). The 20-year longitudinal trajectories of social functioning in individuals with psychotic disorders. *American Journal of Psychiatry*, 174(11), 1075–1085. doi:10.1176/appi.ajp.2016.15111419
- Walther, S., Federspiel, A., Horn, H., Bianchi, P., Wiest, R., Wirth, M., ... Muller, T. J. (2009). Encoding deficit during face processing within the right fusiform face area in schizophrenia. *Psychiatry Research*, 172(3), 184–191. doi:10.1016/j.psychres.2008.07.009
- Williams, J., Farmer, A. E., Ackenheil, M., Kaufmann, C. A., & McGuffin, P. (1996). A multicentre inter-rater reliability study using the OPCRIT computerized diagnostic system. *Psychological Medicine*, 26(4), 775–783. doi:10.1017/s003329170003779x
- Yucel, M., Bora, E., Lubman, D. I., Solowij, N., Brewer, W. J., Cotton, S. M., ... Pantelis, C. (2012). The impact of cannabis use on cognitive functioning in patients with schizophrenia: A meta-analysis of existing findings and new data in a first-episode sample. *Schizophrenia Bulletin*, 38(2), 316–330. doi:10.1093/schbul/sbq079